Martin Jönsson named new CEO of AlzeCure Pharma

Sweden-based CNS specialist AlzeCure Pharma (FN STO: ALZCUR) has appointed Martin Jönsson as its new chief executive with effect on January 9.

Current CEO Johan Sandin, who is also one of the company’s founders, remains with AlzeCure as chief scientific officer and so will continue to be deeply involved in its R&D portfolio candidate drugs.

Mr Jönsson comes most recently from a senior position at Ferring Pharmaceuticals in the USA, where for the past five years, among other things, he was business area director for a number of therapy areas. He has extensive experience from various positions at both Ferring Pharmaceuticals and Roche (ROG: SICX), where he worked with business development, in- and out-licensing of pharmaceuticals, marketing and sales, and alliance management.

"I am happy to welcome Martin as the new CEO of AlzeCure. With over 20 years' experience in the global pharmaceutical industry, and senior positions in several different areas, I'm convinced that Martin is the right person to work intensively with our out-licensing business and continue to develop the broad portfolio of candidate drugs that Johan and the team at AlzeCure have built up," said Thomas Pollare, chairman of AlzeCure Pharma.

AlzeCure is now ready to enter clinical stage and aims to have two candidate drugs in clinic trials by the end of 2020. As the company now enters a new phase, it is a central and natural step to further strengthen the company's leadership with expertise and experience from the business side.

"At the same time, being the company's CEO since its inception, Johan has played a vital role in establishing AlzeCure and leading the company through critical phases, in terms of research as well as financially and organisationally, including the listing on Nasdaq First North Premier Growth Market just over a year ago. I look forward to continue working with Johan when he, at his own request, enters another operational role in the company, with the responsibility for AlzeCure's clinical and pre-clinical research," Thomas Pollare continued.